# JAVELIN PARP MEDLEY (NCT03330405)

> Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

No report yet. It can be ordered.

- Drugs tested: avelumab plus talazoparib
- Indication: locally advanced or metastatic solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03330405
- Phase: PHASE1, PHASE2
- Status: TERMINATED
- Sponsor: Pfizer
- Conditions: Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
- Interventions: Avelumab Phase 1b; Talazoparib Phase 1b; Avelumab Phase 2; Talazoparib Phase 2
- Enrollment: 223
- Primary outcome: Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs)
- Primary outcome: Phase 2: Percentage of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment
- Primary outcome: Phase 2: Percentage of Participants With Confirmed Objective Response (OR) as Per RECIST v1.1 and Prostate Cancer Working Group 3 (PCWG3) by Investigator Assessment

## Indexed commentary on JAVELIN PARP MEDLEY so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=javelin-parp-medley-nct03330405